The prevalence of XXXX is higher in adult survivors of childhood @entity5 .

@entity1 @entity13897 @entity28 @entity5 @entity41910 @entity854
BACKGROUND: It is unclear whether the rate of @entity41910 in paediatric @entity5 survivors is higher than in the background population, and whether this is of pathological significance. @entity1 AND METHODS: 25OHD was measured in a previously studied group of 208 survivors (n  =  108 paediatric 5-17  years, n  =  99 adults 18-39  years) and compared with paediatric (5-17  years; n  =  132) and adult controls (25-35  years; n  =  1393 from the AusDiab cohort) adjusted for age and gender. Relationships with treatment factors (irradiation, bone marrow transplantation and intensity of treatment) along with overweight/ @entity28 (defined by BMI), abdominal adiposity (waist:height ratio >0  5) and @entity13897 ( @entity13897 ) were sought. RESULTS: 25OHD concentrations were similar in paediatric survivors compared with controls (64  3      21  6  nmol/l vs 66  3     22  8  nmol/l), with no effect of age or gender. Adjusted for gender, rates of 25OHD deficiency (<50  nmol/l) were higher in adult survivors compared with AusDiab controls (42  4% vs 20  8%; P  <  0  001). Apart from time since diagnosis (P  =  0  03), no relationship with treatment factors was detected. In multivariate regression analysis, abdominal adiposity (P  =  0  001), but not overweight/ @entity28 by BMI status nor @entity13897 , was associated with significantly lower 25OHD concentrations. CONCLUSIONS: Adult survivors are at increased risk of @entity854 compared to the background population, probably reflecting longer time since diagnosis. Like others, we have not identified any contributory treatment-related factors. @entity41910 does not appear to be associated with the development of @entity13897 in this population.
